Showing results (81-90 of 100) with videos related to
Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II StudySara M Tolaney, Kevin Kalinsky, Virginia G Kaklamani, et al.Cancer Treatment Reviews|February 1, 2008
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxelMinetta C Liu, George D Demetri, Donald A Berry, et al.Breast Cancer Research : BCR|April 19, 2015
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survivalDenise A Yardley, Peter A Kaufman, Weidong Huang, et al.Breast Cancer Research and Treatment|June 21, 2020
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancerMary D Chamberlin, Jason D Wells, Kevin Shee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.The Lancet. Oncology|May 1, 2018
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trialSonia Pernas, Miguel Martin, Peter A Kaufman, et al.Clinical Breast Cancer|May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer SymposiumKomal Jhaveri, Carey K Anders, Aditya Bardia, et al.Pageof 10